STEFANI ALEXANDER: Open Payments
NPI 1659444933 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$904 in 52 payments from 15 companies in 2025. Trend: 2023 $1,050 · 2024 $1,074 · 2025 $904
Food & beverage: $904
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $201 |
| Neurocrine BioSciences, Inc. | 7 | $159 |
| Lundbeck LLC | 5 | $102 |
| Vanda Pharmaceuticals Inc. | 3 | $90 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $59 |
| Corium, LLC | 2 | $53 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| LivaNova USA, Inc. | 1 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $29 |
Products named: VRAYLAR, INGREZZA, REXULTI, FANAPT, CAPLYTA, Azstarys, Auvelity, Qelbree.
Industry payments across TX — which companies pay providers there.
